Advertisement

Cardiac Tissue Engineering Models of Inherited and Acquired Cardiomyopathies

  • Irene C. Turnbull
  • Joshua Mayourian
  • Jack F. Murphy
  • Francesca Stillitano
  • Delaine K. Ceholski
  • Kevin D. Costa
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1816)

Abstract

The lack of biomimetic in vitro models of the human heart has posed a critical barrier to progress in the field of modeling cardiac disease. Human engineered cardiac tissues (hECTs)—autonomous, beating structures that recapitulate key aspects of native cardiac muscle physiology—offer an attractive alternative to traditional in vitro models. Here we describe the use of hECTs to advance our understanding and modeling of cardiac diseases in order to test therapeutic interventions, with a focus on contractile dysfunction in the setting of inherited and acquired forms of cardiomyopathies. Four major procedures are discussed in this chapter: (1) preparation of hECTs from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) on single-tissue and multitissue bioreactors; (2) data acquisition of hECT contractile function on both of these platforms; (3) hECT modeling of hereditary phospholamban-R14 deletion-dilated cardiomyopathy; and (4) cryo-injury and doxorubicin-induced hECT models of acquired cardiomyopathy.

Key words

Tissue engineering Genetic cardiomyopathy Acquired cardiomyopathy Contractility Models of disease Stem cells 

Notes

Acknowledgments

This work was supported by NIH/NHLBI K01HL133424 (ICT), NIH/NHLBI 1F30HL134283-01A1 (JM), American Heart Association 15POST25090116 (DKC), and NIH/NHLBI R01HL132226 (KDC).

References

  1. 1.
    Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE (2006) Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296(15):1867–1876. https://doi.org/10.1001/jama.296.15.1867CrossRefPubMedGoogle Scholar
  2. 2.
    Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM (2014) Rationale and design of the percutaneous stem cell injection delivery effects on neomyogenesis in dilated cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res 7(9):769–780. https://doi.org/10.1007/s12265-014-9594-0CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Turnbull IC, Karakikes I, Serrao GW, Backeris P, Lee JJ, Xie C, Senyei G, Gordon RE, Li RA, Akar FG, Hajjar RJ, Hulot JS, Costa KD (2014) Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J 28(2):644–654. https://doi.org/10.1096/fj.13-228007CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mayourian J, Ceholski DK, Gonzalez DM, Cashman TJ, Sahoo S, Hajjar RJ, Costa KD (2018) Physiologic, pathologic, and therapeutic paracrine modulation of cardiac excitation-contraction coupling. Circ Res 122(1):167–183CrossRefGoogle Scholar
  5. 5.
    Mayourian J, Cashman TJ, Ceholski DK, Johnson BV, Sachs D, Kaji DA, Sahoo S, Hare JM, Hajjar RJ, Sobie EA, Costa KD (2017) Experimental and computational insight into human mesenchymal stem cell paracrine signaling and heterocellular coupling effects on cardiac contractility and arrhythmogenicity. Circ Res 121(4):411–423. https://doi.org/10.1161/CIRCRESAHA.117.310796CrossRefPubMedGoogle Scholar
  6. 6.
    Serrao GW, Turnbull IC, Ancukiewicz D, Kim DE, Kao E, Cashman TJ, Hadri L, Hajjar RJ, Costa KD (2012) Myocyte-depleted engineered cardiac tissues support therapeutic potential of mesenchymal stem cells. Tissue Eng Part A 18(13–14):1322–1333. https://doi.org/10.1089/ten.TEA.2011.0278CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Stillitano F, Turnbull IC, Karakikes I, Nonnenmacher M, Backeris P, Hulot JS, Kranias EG, Hajjar RJ, Costa KD (2016) Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur Heart J 37(43):3282–3284. https://doi.org/10.1093/eurheartj/ehw307CrossRefPubMedGoogle Scholar
  8. 8.
    Strungs EG, Ongstad EL, O’Quinn MP, Palatinus JA, Jourdan LJ, Gourdie RG (2013) Cryoinjury models of the adult and neonatal mouse heart for studies of scarring and regeneration. Methods Mol Biol 1037:343–353. https://doi.org/10.1007/978-1-62703-505-7_20CrossRefPubMedGoogle Scholar
  9. 9.
    Toyoda Y, Okada M, Kashem MA (1998) A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration. J Thorac Cardiovasc Surg 115(6):1367–1373. https://doi.org/10.1016/S0022-5223(98)70221-1CrossRefPubMedGoogle Scholar
  10. 10.
    Karakikes I, Senyei GD, Hansen J, Kong CW, Azeloglu EU, Stillitano F, Lieu DK, Wang J, Ren L, Hulot JS, Iyengar R, Li RA, Hajjar RJ (2014) Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med 3(1):18–31. https://doi.org/10.5966/sctm.2013-0110CrossRefPubMedGoogle Scholar
  11. 11.
    Cashman TJ, Josowitz R, Gelb BD, Li RA, Dubois NC, Costa KD (2016) Construction of defined human engineered cardiac tissues to study mechanisms of cardiac cell therapy. J Vis Exp 109:e53447. https://doi.org/10.3791/53447CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Irene C. Turnbull
    • 1
  • Joshua Mayourian
    • 1
  • Jack F. Murphy
    • 1
  • Francesca Stillitano
    • 1
  • Delaine K. Ceholski
    • 1
  • Kevin D. Costa
    • 1
  1. 1.Cardiovascular Research CenterIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations